Increasing evidence suggests that total intravenous anaesthesia (TIVA) may be the preferred anaesthetic for cancer resection surgery. To assist the preparation of a randomised controlled trial (RCT) examining Volatile (versus TIVA) Anaesthesia and Perioperative Outcomes Related to Cancer (VAPOR-C) we developed an 18-question electronic survey to investigate practice patterns and perspectives (emphasising indications, barriers, and impact on cancer outcomes) of TIVA versus inhalational general anaesthesia in Australasia. The survey was emailed to 1,000 (of 5,300 active Fellows) randomly selected Australian and New Zealand College of Anaesthetists (ANZCA) Fellows. The response rate was 27.5% (n=275). Of the respondents, 18% use TIVA for the majority of cases. In contrast, 46% use TIVA 20% of the time or less. Respondents described indications for TIVA as high risk of nausea, neurosurgery, and susceptibility to malignant hyperthermia. Lack of equipment, lack of education and cost were not considered barriers to TIVA use, and a significant proportion (41%) of respondents would use TIVA more often if setup were easier. Of the respondents, 43% thought that TIVA was associated with less cancer recurrence than inhalational anaesthesia, while 46% thought that there was no difference. Yet, only 29% of respondents reported that they use TIVA often or very often for cancer surgery. In Australasia, there is generally a low frequency of TIVA use despite a perception of benefit when compared with inhalational anaesthesia. Anaesthetists are willing to use TIVA for indications where sufficient evidence supports a meaningful level of improvement in clinical outcome. The survey explores attitudes towards use of TIVA for cancer surgery and demonstrates equipoise in anaesthetists' opinions regarding this indication. The inconsistent use of TIVA in Australasia, minimal barriers to its use, and the equipoise in anaesthetists' opinions regarding the effect of TIVA versus inhalational anaesthesia on cancer outcomes support the need for a large prospective RCT.
Total intravenous anaesthesia (TIVA) offers an alternative to volatile inhalational anaesthesia for maintenance of general anaesthesia. TIVA achieves superior outcomes for adult patients at high risk of postoperative nausea and vomiting (PONV), improves recovery, and reduces postoperative agitation in paediatric patients [1] [2] [3] . TIVA may also improve surgical conditions, with reduced blood loss in facial surgery 4 , and allows more effective visual evoked potential monitoring during spinal surgery 5 . In contrast, inhalational anaesthesia may offer other advantages, including ease of use for induction in paediatric patients, and improved cerebral and cardiac protection 6 and reduced postoperative pulmonary complications and mortality following cardiac surgery 7, 8 . More recently, a large retrospective, propensity-score matched study found an association between volatile anaesthetic exposure (compared with TIVA) during cancer surgery and earlier death (hazard ratio 1.59; interval: 1.30-1.95, P <0.001) 9 . This, together with increasing evidence from in vitro, animal, and other retrospective clinical studies [10] [11] [12] suggests that TIVA may be the preferred anaesthetic for cancer resection surgery. In fact, biological plausibility may be found in the potential anti-inflammatory properties of propofol and the pro-angiogenic and immune suppressive properties of volatiles 11, 12 .
As the incidence of cancer increases globally, more patients will present for surgical resection of both primary and metastatic solid tumours and thus require exposure to anaesthetic agents. Currently, it is estimated that more than 80% of patients with cancer require anaesthesia for either definitive cancer resection (approximately 60%) or for diagnostic (e.g. biopsies), supportive (e.g. vascular access device insertion), or palliative procedures 10, 13, 14 . Elucidating the optimal anaesthetic techniques in cancer surgery is thus pivotal, and large prospective randomised controlled trials (RCTs) are warranted 15 . To explore the feasibility of conducting a large prospective RCT examining Volatile (versus TIVA) Anaesthesia and Perioperative Outcomes Related to Cancer (VAPOR-C-ACTRN 12617001065381), we undertook this survey to establish current practice patterns of general anaesthesia techniques in Australasia. More specifically, we aimed to identify anaesthetists' current indications for use of TIVA, barriers to use, and their perspectives on the use of TIVA for cancer surgery.
Materials and methods
An electronic survey was designed using SurveyMonkey (Palo Alto, CA, USA) with answers automatically captured in an Excel file. The survey was developed by the authors, with item generation based on literature review and nomination based on clinical experience. Item reduction occurred by consensus and the survey was then assessed to ensure satisfactory content validity. The survey consisted of 18 questions across the domains of demographics, practice patterns and perspectives (emphasising indications, barriers, and perceived impact on cancer outcomes) on delivery of TIVA versus inhalational general anaesthesia. Each question allowed a single response only. Questions examining practices and perspectives were designed using five-and seven-point Likert scales, supplemented with percentages to provide guidance to respondents where applicable. The number of questionnaire items per page ranged from one to 13, with a total of nine pages. The participants could review and change their answers before submitting the survey.
The survey was piloted among 26 anaesthetists at Peter MacCallum Cancer Centre to ensure that the survey satisfactorily addressed primary and secondary endpoints and was participant-friendly. Following institutional ethics approval (Peter MacCallum Cancer Centre HREC/17/ PMCC/62) and approval by the Australian and New Zealand College of Anaesthetists (ANZCA) Clinical Trials Network for distribution, the survey was distributed to 1,000 ANZCA active Fellows (out of approximately 5,300 active Fellows) via email in July 2017. A simple random sample, without replacement, of 1,000 active Fellows was taken from the College's database of 5,700 Fellows via a script. A participant consent form was integrated as part of the electronic survey interface. Respondents were required to read the consent form and explicitly offer consent at the beginning of the survey in order to access and complete further survey questions. Respondents were asked to consider their principal place of practice when answering the questions, and to consider questions as if they were providing general anaesthesia for surgical procedures lasting more than two hours. Multiple responses were prevented by use of cookies by SurveyMonkey. Allocation was blinded, internet protocol addresses were not logged and all responses remained anonymous. All respondents received a single email reminder two weeks after the initial email distribution, as per the ANZCA Clinical Trials Network protocol. Non-response was assumed if no survey was completed within four weeks following the initial email. No incentives were offered to respondents.
Quantitative survey data were summarised descriptively using counts and proportions. Missing answers were not included in the nominator or denominator. A chi-square test was used to compare differences between the following groups using a two-sided significance level of 0. , the usage of TIVA for cancer surgery (never/ rarely, sometimes, often/very often) against opinion on the association of TIVA with cancer recurrence risk (less, same/ higher), and the frequency of providing cancer anaesthesia (less than one, one or more major cancer resection cases per week) against the opinion of the impact of TIVA on cancer recurrence (strongly to somewhat disagree, same, somewhat to strongly agree). All summaries and statistical tests were performed using Microsoft® Excel® 2013 (Microsoft Corporation, Redmond, WA, USA 2012), Prism 7 (GraphPad Software, La Jolla, CA, USA) and themes were drawn from recurring comments. 
Results

Demographics
There were 275 (27.5%) unique respondents who provided consent and completed the survey. Of these, 260 (94.5%) completed all survey questions. The demographic profile of the respondents is presented in Table 1 . Respondents represented all Australian states, with the most common locations being New South Wales (71, 27%), Victoria (59, 21%), and Queensland (56, 20%). A total of 38 (14%) respondents practised in New Zealand and one respondent practised in Singapore. There was a fairly even split between anaesthetists who practice predominantly in public hospitals (149, 54%) and those who do a significant component (50% or more) of their work in the setting of private hospitals (125, 46%). 
Practice patterns
Indications and method of use for TIVA
The most common indications for use of TIVA included: patients susceptible to malignant hyperthermia (245, 97% very often), patients with multiple risk factors for nausea and vomiting (132, 50% very often) and patients having neurosurgery (81, 55% very often). There was even spread between respondents who would rarely (94, 36%), sometimes (81, 31%), and often or very often (75, 29%) use TIVA for cancer surgery. Data are summarised in Figure 1 .
A total of 225 (84%) respondents preferred using a pharmacokinetic model for propofol infusion when administering TIVA. Preferred pharmacokinetic models were reported as Marsh plasma concentration targeted (85, 32%), Schnider effect-site concentration targeted (73, 27%), Marsh effect-site concentration targeted (53, 20%), and Schnider plasma concentration targeted (14, 5%). Infusion rate (e.g. ml/hour, mg/kg/hour) was the preferred method of administration for 27 (10%) respondents. Of the 15 (6%) respondents who selected other, the majority stated that they used paediatric Paedfusor or Kataria algorithms.
Respondents reported use of a wide range of pharmacologic agents within their TIVA regimen ( Table 2) . The most popular adjuncts used were fentanyl (121, 46% often or very often), remifentanil (123, 46% often or very often) and benzodiazepines (114, 44% often or very often).
Free-text comments from respondents suggested that ketamine and clonidine were additional common adjuncts.
Perspectives on technical aspects and barriers
When asked to compare anaesthesia techniques, respondents perceived TIVA to have several technical (Figure 3 ), 41% (n=108) of respondents agreed or strongly agreed they would use TIVA more often if it were easier to set up. The majority of respondents reported that they did not perceive institutional restriction of use of TIVA (no restriction for 253, 98%) and depth of anaesthesia monitoring (no restriction for 250, 96%) as barriers to TIVA use. A total of 216 (83%) respondents reported routine use of depth of anaesthesia monitoring during TIVA. Of the respondents, 58% (n=150) felt that their operating rooms had sufficient pharmacokinetic programmable pumps to enable administration of TIVA in all operating rooms at the same time, and an additional 23% (n=60) were able to access pharmacokinetic pumps in over 75% of operating rooms. Respondents' facilities had similar capacity for simultaneous depth of anaesthesia monitoring: 63% (n=164) had capacity to utilise simultaneous monitoring in all operating rooms, and an additional 22% (n=58) were able to utilise it in over 75% of operating rooms. In addition to equipment, cost and lack of education and familiarity with TIVA and pharmacokinetic models were not perceived barriers to TIVA use.
Perspectives on clinical impact of TIVA compared to inhalational anaesthesia
Data are summarised in Figure 4 . Respondents strongly agreed that propofol-based TIVA was associated with a reduced risk of malignant hyperthermia (203, 77% strongly agree) and less PONV (203, 77% agree or strongly agree). Respondents agreed that TIVA provided less emergence delirium (208, 79% somewhat to strongly agree), better quality of recovery (208, 79% somewhat to strongly agree), better patient satisfaction (167, 64% somewhat to strongly agree), and better neuroprotection (164, 64% somewhat to strongly agree).
With respect to long-term postoperative sequelae, respondents did not perceive a clear benefit to the use of TIVA for neurocognitive recovery (159, 61% thought TIVA had the same outcome as inhalational anaesthesia) or improving cancer outcomes (121, 46% thought TIVA had the same outcome on cancer recurrence as inhalational anaesthesia). Opposing this, 111 (43%) respondents thought that TIVA was associated with less risk of cancer recurrence. Respondents who thought that TIVA was associated with a lower risk of cancer recurrence had significantly higher usage of TIVA for cancer surgery (49% often/very often) than those who thought that TIVA was associated with the same or higher risk (15% often/very often) (P <0.001).
Respondents were asked how many patients scheduled for 'major' cancer resection surgery would be under their perioperative care on a weekly basis: 53% (n=137) reported less than one patient per week, 33% (n=87) one to two cases per week, and only 14% (n=36) reported two or more cases per week. Among respondents who did less than one major cancer resection case per week, a total of 49% (n=65) think there is no difference while 43% (n=58) agree that TIVA is associated with less risk of cancer recurrence. In comparison, among those who provided more frequent anaesthesia for cancer surgery 15% (n=18) disagree, 44% (n=54) think there is no difference, and 42% (n=51) agree that TIVA is associated with less risk of cancer recurrence. There was no difference in these opinions between respondents who did or did not do cancer anaesthesia frequently (P=0.26).
Discussion
Our study provides insight into current general anaesthesia practice in Australia and New Zealand.
The response rate (27.5%) is comparable with other ANZCA-distributed surveys and is similar to a recent large international survey by Wong et al 16 (n=842, 22% response rate) that examined barriers to global TIVA use. The focus of our survey was to explore ANZCA Fellows' perceptions of indications for use of TIVA, and to investigate attitudes towards use of TIVA for cancer surgery.
The survey found that 54% of respondents use TIVA sometimes, often, or very often, but only 18% of respondents use TIVA for the majority of cases. Similarly, Wong et al found 16% of respondents use TIVA for the majority of cases. TIVA use has increased from older surveys of UK practice 17, 18 , and this utilisation is consistent across age and place of practice demographics. Overall, Australasian anaesthetists appear comfortable with TIVA use, and readily apply this general anaesthesia technique where there is evidence of clinical benefit. This is supported by the findings by Wong et al that a higher number of infrequent users of TIVA perceived that it gave patients no clinical benefit 16 . Popular indications for TIVA were for patients susceptible to malignant hyperthermia or PONV and for neurosurgical procedures. A contrast is seen between the low level of regular TIVA use and the majority perception of its benefits compared with volatile based anaesthesia on patient-centric outcomes: patient satisfaction, PONV, emergence delirium, neuroprotection and quality of recovery. The lack of more widespread adoption of TIVA therefore suggests that Australasian anaesthetists do not perceive these side-effects to be either frequent or troublesome in their practice, and thus without strong evidence of benefit from TIVA continue a practice dominated by volatile anaesthesia.
Significantly, 41 percent of respondents would use TIVA more often if it were easier to set up. We hypothesise that the perceived barriers to setup relate to relatively low frequency of TIVA use and concerns of maintaining efficiency in theatre lists where fast turnover is required for shorter cases. This is supported by the survey of Wong et al whereby infrequent users identified additional effort, lack of a real-time monitor of propofol concentration and risk of drug delivery failure as barriers to TIVA use 16 . Improvements here may require practical (rather than pharmacological) education relating to TIVA delivery. These include raising awareness of time-saving equipment (e.g. Mini-Spike® 2, 50-100 ml propofol vials, minimum volume infusion lines) and promotion of increasingly prevalent masterclass style seminars on efficient and safe TIVA delivery.
In contrast to the findings of other international surveys 19, 20 , ANZCA Fellows appear to have reliable access to both pumps and depth of anaesthesia monitoring and are comfortable with pump setup. There was a clear preference for administering TIVA using plasma or effect site target-controlled modelling (only ten percent of respondents use fixed infusion strategies) and programmable (pharmacokinetic) pumps are available in more than 80 percent of cases. Wong et al similarly found that the majority (84%) of respondents preferred using a pharmacokinetic model compared with manual infusion. Respondents' concerns of the increased cost of TIVA compared with volatile anaesthesia are supported by published, albeit historical, studies 23 , though the small cost difference is mitigated by the improvements in recovery time and reduced need for antiemesis therapy. That said, based on current costs (2018) we estimated within a small cohort of patients (n=65), randomised to TIVA or volatile anaesthesia for the VAPOR-C feasibility study, that TIVA costs were minimal (propofol-TIVA = A$13.30 ± 7.3 versus volatile = A$87.40 ± 97.1 per case; unpublished data).
Climate change is a priority for the international community. In ratifying the Kyoto Protocol (1997) and Paris Agreement (2015), Australia indicated it would reduce carbon emissions by one quarter of the 2005 levels by 2030. Volatile anaesthetic agents, as hydrofluorocarbons, have a significant greenhouse gas effect (desflurane much greater than sevoflurane). Over 80 percent of ANZCA Fellows also felt that TIVA use, compared with volatile anaesthesia, had a better profile as an environmental pollutant. This perception is supported by a recent study published in Lancet Planetary Health 21 highlighting that volatile anaesthetic gas emissions represent a significant proportion of the carbon footprint of operating theatres, accounting for one-third of the carbon footprint of surgical operating rooms, with an average production of 72.5 kg carbon dioxide per surgical case. Thirty anaesthetics involving desflurane release the equivalent amount of carbon dioxide as a return longhaul intercontinental flight 21, 22 . Extrapolating from current anaesthetic practice, with preference for volatile anaesthesia, we can anticipate 33.3 million tonnes of carbon dioxide emission each year as we strive to deliver the global requirement for 458 million surgical cases per year in 2030. The carbon offset for that would be A$435 million per year.
Interpretation of our data, like any survey-based research, is limited by the response bias and the overall low response rate. Respondents may likely be either enthusiasts or disbelievers of TIVA and thus the results may reflect an average of opposing polarised views.
This survey explores attitudes towards use of TIVA for cancer surgery and demonstrates equipoise in anaesthetists' opinions regarding this indication. Since the recent publication of retrospective studies reporting favourable clinical outcomes for patients receiving propofol-based anaesthesia for cancer surgery 9, 24 , TIVA has been proposed, but still debated, as the anaesthetic of choice for cancer resection surgery 11, 12 . That nearly half of respondents are preferentially using TIVA for cancer surgery, despite current evidence being based only on retrospective cohort studies rather than clinical trials, indicates a surprisingly rapid uptake of interest in the niche subspecialty of onco-anaesthesia. A variation in opinion and practice remains. The data from this study support the equipoise regarding anaesthetists' practice and their opinions about the differential effects of TIVA or volatile-based anaesthesia on cancer outcomes and thus the need for a large pragmatic prospective RCT (VAPOR-C-ACTRN12617001065381). The potential for improved long-term cancer outcomes and the potential for reduced carbon dioxide emissions necessitates urgent research into intravenous anaesthesia as the preferred anaesthetic technique for cancer surgery. The survey results indicate that Australasian anaesthetists have appropriate training, equipment, and interest to participate in a large, multicentre, international study of volatile anaesthesia versus TIVA.
